- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00515879
Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia
D-cycloserine Enhancement of Exposure in Social Phobia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Social anxiety disorder (SAD) is among the most common psychiatric conditions and is associated with significant distress and dysfunction in social situations. Although treatment with cognitive-behavior therapy (CBT) is known to help remedy SAD, many patients do not respond to this treatment and most do not reach full recovery. In CBT, patients undergo repeated and prolonged exposure practices to feared social situations to learn better ways to deal with anxiety in these settings. Exposure therapy is based on animal models of extinction of conditioned fears, and recent animal research has identified some of the core pathways and neurotransmitters involved in fear extinction. D-cycloserine (DCS) is a drug that appears to facilitate learning and the process of extinction of conditioned fear in both animals and humans. This study will assess the effectiveness of DCS combined with CBT in treating people with SAD.
Participants in this double-blind study will be randomly assigned to an active or control group. All participants will attend 18 study visits at the Center for Anxiety and Related Disorders over a 9-month period. There will be 12 CBT sessions of 90 minutes each and 6 assessment visits. The CBT sessions will help participants to become more comfortable with social situations. During 5 of the CBT sessions, participants will receive a pill containing either DCS or sugar (placebo). Assessment visits will include interviews, self-report questionnaires, and laboratory tests. These visits will occur at Weeks 1, 7, and 12 during treatment and at Months 3, 6, and 9 post-treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Boston University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meets DSM-IV criteria for generalized social anxiety disorder (GSAD)
- Total score of greater than or equal to 60 on the LSAS
- Physical examination, electrocardiogram, and laboratory findings without clinically significant abnormalities
Exclusion Criteria:
- Lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders, or obsessive-compulsive disorder
- Eating disorder within the 6 months prior to study entry
- History of organic brain syndrome, mental retardation, or other cognitive dysfunction
- Substance or alcohol abuse or dependence (other than nicotine) within the 6 months prior to study entry or inability to refrain from alcohol use during the acute period of study participation
- Post-traumatic stress disorder within 6 months prior to study entry; entry of patients with other mood or anxiety disorders will be permitted if the social anxiety disorder is judged to be the predominant disorder
- Suicidal thoughts
- Taking concurrent psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers) within 2 weeks of study entry
- Significant personality dysfunction
- Serious medical illness or instability for which hospitalization may be likely within the next year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CBT plus d-cycloserine
Participants will receive cognitive behavioral therapy plus D-cycloserine
|
50 mg
Other Names:
CBT sessions aim to help participants become more comfortable with social situations.
|
Placebo Comparator: CBT plus placebo
Participants will receive cognitive behavioral therapy plus pill placebo
|
CBT sessions aim to help participants become more comfortable with social situations.
Same dosage as active pill
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Social Phobic Disorders Severity and Change Form
Time Frame: Measured at Months 3 (immediately after treatment)
|
Social Phobic Disorders Severity and Change Form (SPD-SC Form; Liebowitz et al., 1992) is an expansion and adaptation of the Clinical Global Impression Scale (CGI) by Guy (1976) to SAD.
Similar to the original CGI scale, the SPD-SC Form is rated by an independent evaluator on a 7-point scale to indicate severity (1=normal/not ill; 2 = minimally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most severely ill) and improvement (1=very much improved; 2=much improved; .
3=minimally improved' 4 = no change; 5=nimimal deterioration; 6=severe deterioration; 7=very severe deterioration).
The primary outcome measure is units of a scale ranging from 1 (very much improved) to 7 (very severe deterioration).
|
Measured at Months 3 (immediately after treatment)
|
Liebowitz Social Anxiety Scale (LSAS)
Time Frame: Measured at Months 3
|
The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) is a 24-item scale that provides separate scores for fear and avoidance in social and performance situations; it is widely used in treatment studies of SAD.
Total scores range from 0 (no anxiety) to 144 (maximum).
|
Measured at Months 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Social Phobia and Anxiety Inventory
Time Frame: Measured at Months 3, 6, and 9 post-treatment
|
The Social Phobia and Anxiety Inventory (SPAI; Turner, Beidel, Dancu, and Stanley, 1989) is a 45-item self-report measure on the frequency (0 = Never, 1 = Very Infrequent, 2 = Infrequent, 3 = Sometimes, 4 = Frequent, 5 = Very Frequent, 6 = Always) of one's experiences.
The inventory includes 32 items assessing somatic, cognitive, and behavioral symptoms of social anxiety and 13 items assessing agoraphobia.
The final score is calculated by subtracting the agoraphobia subscale total (max = 78; min = 0) from the social phobia subscale total (max = 192; min = 0).
Thus, the final total scores range from 0-114, where higher final scores indicate higher social anxiety.
|
Measured at Months 3, 6, and 9 post-treatment
|
Quality of Life Enjoyment and Satisfaction Questionnaire
Time Frame: Measured at Months 3, 6, and 9 post-treatment
|
The Quality of Life Enjoyment and Satisfaction Questionnaire (Endicott et al., 1993) is a 16-item self-report measure that rates aspects of quality of life, including physical health, mood, activities of daily living, and overall life satisfaction.
Responses are scored on a 5 point scale.
The maximum score is 70 (high satisfaction) and the minimum is 14 (low satisfaction); scores are generally expressed as a percentage of maximum total score (0-100).
|
Measured at Months 3, 6, and 9 post-treatment
|
Liebowitz Self-Rated Disability Scale
Time Frame: Measured at Months 3, 6, and 9 post-treatment
|
Liebowitz Self-Rated Disability Scale (Schneier et al., 1994) is an 11-item scale assessing impairment specific to social anxiety.
Current (past 2 weeks) and most severe lifetime impairment due to social anxiety disorder are rated on a 0-3 scale of degree of limitation (0=problem does not limit me at all; 3=problem limits me severely).
The maximum score is 44 (severe impairment) and the minimum is 0 (no impairment).
|
Measured at Months 3, 6, and 9 post-treatment
|
Range of Impaired Functioning Tool
Time Frame: Measured at Months 3, 6, and 9 post-treatment
|
The Range of Impaired Functioning Tool (LIFE-RIFT, Leon et al., 2000) is a clinician rated scale assessing functioning in four domains: work, interpersonal relationships, recreation, and global satisfaction.
Each domain is scored 0-5 (0=not applicable, 1=no impairment, 2=slight impairment, 3=mild impairment, 4=moderate impairment, 5=severe impairment).
The total score is the sum of each domain's score, with a maximum score of 20 (severe impairment) and a minimum score of 4 (no impairment).
|
Measured at Months 3, 6, and 9 post-treatment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Stefan G. Hofmann, PhD, Boston University
- Principal Investigator: Mark H. Pollack, MD, Massachusetts General Hospital
- Study Director: Jasper A. Smits, PhD, Southern Methodist University
Publications and helpful links
General Publications
- Hofmann SG, Pollack MH, Otto MW. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev. 2006 Fall-Winter;12(3-4):208-17. doi: 10.1111/j.1527-3458.2006.00208.x.
- Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG. Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectr. 2007 Jan;12(1):51-6, 59-61. doi: 10.1017/s1092852900020526.
- Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006 Mar;63(3):298-304. doi: 10.1001/archpsyc.63.3.298.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01MH078308 (U.S. NIH Grant/Contract)
- R01MH075889 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Social Anxiety Disorder
-
Aya Technologies LimitedCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)United Kingdom
-
Tel Aviv UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)Israel
-
Aya Technologies LimitedCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)United Kingdom
-
University of BernUniversity of LuebeckActive, not recruitingSocial Anxiety Disorder (Social Phobia)Switzerland
-
Daniel LiebermanTerminatedAnxiety | Anxiety Disorder SocialUnited States
-
Weill Medical College of Cornell UniversityBrain & Behavior Research FoundationTerminatedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States
-
Tufts UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States
-
Sumitomo Pharma America, Inc.BehaVR LLCCompletedSocial Anxiety Disorder (SAD)United States
-
Emory UniversityBristol-Myers SquibbCompleted
-
Florida International UniversityYale UniversityRecruitingSocial Anxiety Disorder of ChildhoodUnited States
Clinical Trials on D-cycloserine
-
Mclean HospitalUniversity of MinnesotaCompletedSchizophrenia | Bipolar Disorder
-
University of Texas at AustinBoston University; Rush University Medical Center; Southern Methodist UniversityCompletedSocial Anxiety DisorderUnited States
-
University of OxfordNational Health Service, United KingdomUnknownChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Northwestern UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...TerminatedChronic Prostatitis With Chronic Pelvic Pain SyndromeUnited States
-
Yale UniversityCompletedAlcohol DependenceUnited States
-
University of California, Los AngelesUnknownTraumatic Brain InjuryUnited States
-
US Department of Veterans AffairsCompleted
-
University of ArkansasNational Institute on Drug Abuse (NIDA)Completed
-
Northwestern UniversityTerminatedPain | Breast Cancer | NeurotoxicityUnited States
-
Hoffmann-La RocheCompletedHepatitis C, ChronicNew Zealand, Australia